KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Cost of Revenue: 2011-2024

Historic Cost of Revenue for Pacira BioSciences (PCRX) over the last 14 years, with Dec 2024 value amounting to $170.4 million.

  • Pacira BioSciences' Cost of Revenue fell 11.80% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.3 million, marking a year-over-year decrease of 16.21%. This contributed to the annual value of $170.4 million for FY2024, which is 7.71% down from last year.
  • Latest data reveals that Pacira BioSciences reported Cost of Revenue of $170.4 million as of FY2024, which was down 7.71% from $184.7 million recorded in FY2023.
  • Pacira BioSciences' 5-year Cost of Revenue high stood at $199.3 million for FY2022, and its period low was $117.3 million during FY2020.
  • Over the past 3 years, Pacira BioSciences' median Cost of Revenue value was $184.7 million (recorded in 2023), while the average stood at $184.8 million.
  • As far as peak fluctuations go, Pacira BioSciences' Cost of Revenue soared by 42.09% in 2022, and later dropped by 7.71% in 2024.
  • Over the past 5 years, Pacira BioSciences' Cost of Revenue (Yearly) stood at $117.3 million in 2020, then increased by 19.54% to $140.3 million in 2021, then spiked by 42.09% to $199.3 million in 2022, then declined by 7.34% to $184.7 million in 2023, then fell by 7.71% to $170.4 million in 2024.